Hong Kong · Delayed Price · Currency is HKD InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 32.23 billion. The enterprise value is 26.18 billion.
| Market Cap | 32.23B |
| Enterprise Value | 26.18B |
Important Dates
The last earnings date was Wednesday, March 25, 2026.
| Earnings Date | Mar 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.70 billion shares outstanding. The number of shares has decreased by -0.24% in one year.
| Current Share Class | 1.43B |
| Shares Outstanding | 1.70B |
| Shares Change (YoY) | -0.24% |
| Shares Change (QoQ) | +6.02% |
| Owned by Insiders (%) | 20.52% |
| Owned by Institutions (%) | 29.12% |
| Float | 1.05B |
Valuation Ratios
The trailing PE ratio is 37.43 and the forward PE ratio is 151.86.
| PE Ratio | 37.43 |
| Forward PE | 151.86 |
| PS Ratio | 12.20 |
| PB Ratio | 3.74 |
| P/TBV Ratio | 3.87 |
| P/FCF Ratio | 2,107.72 |
| P/OCF Ratio | 345.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 41.98, with an EV/FCF ratio of 1,711.96.
| EV / Earnings | 36.62 |
| EV / Sales | 9.91 |
| EV / EBITDA | 41.98 |
| EV / EBIT | 52.02 |
| EV / FCF | 1,711.96 |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.83 |
| Quick Ratio | 5.47 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.88 |
| Debt / FCF | 117.24 |
| Interest Coverage | 8.36 |
Financial Efficiency
Return on equity (ROE) is 8.89% and return on invested capital (ROIC) is 24.61%.
| Return on Equity (ROE) | 8.89% |
| Return on Assets (ROA) | 2.79% |
| Return on Invested Capital (ROIC) | 24.61% |
| Return on Capital Employed (ROCE) | 4.79% |
| Weighted Average Cost of Capital (WACC) | 6.37% |
| Revenue Per Employee | 2.25M |
| Profits Per Employee | 607,946 |
| Employee Count | 1,176 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, InnoCare Pharma has paid 12.86 million in taxes.
| Income Tax | 12.86M |
| Effective Tax Rate | 1.76% |
Stock Price Statistics
The stock price has increased by +85.80% in the last 52 weeks. The beta is 0.42, so InnoCare Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +85.80% |
| 50-Day Moving Average | 12.72 |
| 200-Day Moving Average | 14.76 |
| Relative Strength Index (RSI) | 73.37 |
| Average Volume (20 Days) | 10,484,885 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 2.64 billion and earned 714.94 million in profits. Earnings per share was 0.42.
| Revenue | 2.64B |
| Gross Profit | 2.43B |
| Operating Income | 503.32M |
| Pretax Income | 729.72M |
| Net Income | 714.94M |
| EBITDA | 590.39M |
| EBIT | 503.32M |
| Earnings Per Share (EPS) | 0.42 |
Balance Sheet
The company has 7.87 billion in cash and 1.79 billion in debt, with a net cash position of 6.08 billion or 3.58 per share.
| Cash & Cash Equivalents | 7.87B |
| Total Debt | 1.79B |
| Net Cash | 6.08B |
| Net Cash Per Share | 3.58 |
| Equity (Book Value) | 8.62B |
| Book Value Per Share | 4.45 |
| Working Capital | 7.43B |
Cash Flow
In the last 12 months, operating cash flow was 93.37 million and capital expenditures -78.07 million, giving a free cash flow of 15.29 million.
| Operating Cash Flow | 93.37M |
| Capital Expenditures | -78.07M |
| Depreciation & Amortization | 89.73M |
| Net Borrowing | -3.56M |
| Free Cash Flow | 15.29M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 91.95%, with operating and profit margins of 19.04% and 27.05%.
| Gross Margin | 91.95% |
| Operating Margin | 19.04% |
| Pretax Margin | 27.61% |
| Profit Margin | 27.05% |
| EBITDA Margin | 22.34% |
| EBIT Margin | 19.04% |
| FCF Margin | 0.58% |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.12% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 0.24% |
| Earnings Yield | 2.22% |
| FCF Yield | 0.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 4.85 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.85 |
| Piotroski F-Score | 6 |